Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to Manufacture siRNA for Intradigm Rx

NEW YORK (GenomeWeb News) — Agilent Technologies will manufacture the small-interfering RNA component of an RNAi therapeutic being developed by Intradigm, the firms said last week.
Agilent will supply the siRNA material for use in Intradigm’s preclinical oncology candidate, ICS-283. According to the firms, ICS-283 is the only RNAi therapeutic in development against a clinically validated oncology target, in this case vascular endothelial growth factor.
Intradigm has developed the RNAi Nanoplex delivery system for administering RNAi therapeutics.
Financial terms of the alliance were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.